D. Getsios

发表

Discrete event simulation: the preferred technique for health economic evaluations?

Jörgen Möller, Jaime J Caro, Denis Getsios, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Adult Vaccination Strategies for the Control of Pertussis in the United States: An Economic Evaluation Including the Dynamic Population Effects

J. Caro, D. Getsios, L. Coudeville, 2009, PloS one.

Sumatriptan: Economic Evidence for Its Use in the Treatment of Migraine, the Canadian Comparative Economic Analysis

D. Getsios, G. Raggio, J. Caro, 2001, Cephalalgia : an international journal of headache.

Pharmacoeconomic evidence and considerations for triptan treatment of migraine

J. Caro, D. Getsios, 2002, Expert opinion on pharmacotherapy.

NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors

J. Caro, D. Getsios, K. Migliaccio-Walle, 2012, PharmacoEconomics.

Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the US

D. Getsios, S. Dixit, I. Proskorovsky, 2015, Journal of medical economics.

Pertussis Immunization of Adolescents in the United States: An Economic Evaluation

J. Caro, D. Getsios, J. O'brien, 2005, The Pediatric infectious disease journal.

Instituting a routine varicella vaccination program in Canada: an economic evaluation

J. Caro, D. Getsios, G. Caro, 2002, The Pediatric infectious disease journal.

Economic assessments of low molecular weight heparin in venous thromboembolism

J. Caro, D. Getsios, A. Ward, 2004, Expert review of pharmacoeconomics & outcomes research.

Pharmacological management of overactive bladder

J. Caro, D. Getsios, W. El-Hadi, 2012, PharmacoEconomics.

Oxybutynin Extended Release and Tolterodine Immediate Release

J. Caro, D. Getsios, D. Dubois, 2004, Clinical drug investigation.

PND10 COST-EFFECTIVENESS STUDY IN PATIENTS WITH MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE: PROJECTED BENEFITS OF DONEPEZIL IN THE UNITED KINGDOM

D. Getsios, S. Blume, G. Maclaine, 2009 .

PND11 COST-EFFECTIVENESS OF SCREENING AND TREATMENT OF ALZHEIMER'S DISEASE WITH DONEPEZIL IN THE UNITED KINGDOM

D. Getsios, S. Blume, G. Maclaine, 2009 .

Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder.

J. Caro, D. Getsios, K. Payne, 2004, Clinical therapeutics.

Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: A review and recommendations for further research

J. Caro, D. Getsios, W. El-Hadi, 2004, International Journal of Technology Assessment in Health Care.

Economic Burden of Pertussis and the Impact of Immunization

J. Caro, D. Getsios, L. Annemans, 2005, The Pediatric infectious disease journal.

Managing meningococcal disease in the United States: Hospital case characteristics and costs by age.

J. Caro, D. Getsios, J. O'brien, 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Treatment of Migraine in Canada With Naratriptan: A Cost‐Effectiveness Analysis

D. Getsios, G. Raggio, J. Caro, 2001, Headache.

PCV27 THE PREDICTION OF STROKE AND MORTALITY OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION MAINTAINING SINUS RHYTHM WITH AND WITHOUT ANTIARRHYTHMIC DRUGS

D. Getsios, Y. Khaykin, P. Quon, 2009 .

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

J. Caro, D. Getsios, J. O'brien, 2003, Clinical therapeutics.

Invasive meningococcal disease epidemiology and control measures: a framework for evaluation

J. Caro, J. Möller, D. Getsios, 2007, BMC public health.

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

D. Getsios, Christopher Salvador, T. Kongnakorn, 2014, ClinicoEconomics and outcomes research : CEOR.

Long-Term Effects of Second-Generation Cholinesterase Inhibitors on Clinical Outcomes and Costs of Alzheimer’s Disease

J. Caro, D. Getsios, 2003 .

Smoking Cessation Treatment and Outcomes Patterns Simulation: A New Framework for Evaluating the Potential Health and Economic Impact of Smoking Cessation Interventions

R. Willke, D. Getsios, A. Ward, 2013, PharmacoEconomics.

Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease

D. Getsios, Asli Ozen, L. Hernandez, 2016, PharmacoEconomics.

Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada

J. Caro, D. Getsios, J. O'brien, 2004, Diabetic medicine : a journal of the British Diabetic Association.

Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

J. Caro, D. Getsios, A. Ward, 2002, Dementia and Geriatric Cognitive Disorders.

Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model

D. Getsios, P. McEwan, J. Jaime Caro, 2007 .

Cost Effectiveness of Tinzaparin Sodium Versus Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis

J. Caro, D. Getsios, J. O'brien, 2012, PharmacoEconomics.

Inclusion of Compliance and Persistence in Economic Models

D. Getsios, S. Sorensen, A. Kansal, 2012, Applied Health Economics and Health Policy.

Inclusion of compliance and persistence in economic models: past, present and future.

D. Getsios, S. Sorensen, A. Kansal, 2012, Applied health economics and health policy.

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps

Kelly Cho, Denis Getsios, Elizabeth Lawler, 2012, International journal of Alzheimer's disease.

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

Denis Getsios, Susanne Hartz, D. Getsios, 2012, BMC Neurology.

Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease

Denis Getsios, D. Getsios, Steve Blume, 2012, PharmacoEconomics.

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK

J. Caro, D. Getsios, R. Bullock, 2003, PharmacoEconomics.

Diabetes in Canada: direct medical costs of major macrovascular complications.

D. Getsios, J. O'brien, J. Caro, 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease

D. Getsios, G. Thompson, M. Gaudig, 2014, PharmacoEconomics.

NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Jaime J Caro, Denis Getsios, J. Caro, 2007, PharmacoEconomics.

Assessment of Health Economics in Alzheimer’s Disease (AHEAD)

J. Caro, B. Winblad, A. Wimo, 2012, PharmacoEconomics.

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

J. Caro, D. Getsios, J. Ishak, 2003, BMC geriatrics.

Assessment of health economics in Alzheimer’s disease (AHEAD)

J. Caro, D. Getsios, G. Caro, 2001, Neurology.

Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time care

J. Caro, D. Getsios, A. Ward, 2001, Neurology.

Assessing the Health and Economic Impact of Galantamine Treatment in Patients with Alzheimer’s Disease in the Health Care Systems of Different Countries

J. Caro, D. Getsios, A. Ward, 2004, Drugs & aging.

Accounting for the relationship between per diem cost and LOS when estimating hospitalization costs

D. Getsios, M. Stolar, Yamei Wang, 2012, BMC Health Services Research.

Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.

J. Caro, D. Getsios, W. El-Hadi, 2005, PharmacoEconomics (Auckland).

To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?

Denis Getsios, Alexandra Ward, Jaime Caro, 2002, BMC neurology.

Improved perioperative blood pressure control leads to reduced hospital costs

D. Getsios, M. Stolar, Yamei Wang, 2013, Expert opinion on pharmacotherapy.

Model-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study.

J. Benichou, L. Abenhaim, D. Getsios, 2016, Journal of clinical lipidology.